Interstitial Lung Disease including IPF (Idiopathic Pulmonary Fibrosis) Lung Cancer
Conditions
Interventions
None listed
Sponsors
National Institutes of Biomedical Innovation, Health and Nutrition
Osaka University Kanagawa Cardiovascular and Respiratory Center National Cancer Center Tokushima University Kyoto University Nara Institute of Science and Technology Ochanomizu University Kyushu Institute of Technology RIKEN Karydo TherapeutiX, Inc. MEDICAL &
BIOLOGICAL LABORATORIES CO., LTD.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: *Interstitial pneumonia including IPF (including suspicion) Those who meet the conditions (1)-(5): (1) Patients with interstitial pneumonia including IPF (including suspicion) who visited the hospital between April 1, 2012 and March 31, 2025. (2) Patients who can provide consent to participate in this study for themselves. (3) Patients aged 16 years or older at the time of obtaining consent. (4) For both male and female (5) For both inpatient and outpatient *Lung cancer (1)Patients who have been diagnosed with lung cancer and have provided consent for surgery. (2) No age limitation. (3) No other specific criteria for inclusion.
Exclusion criteria
Exclusion criteria: *Interstitial pneumonia including IPF (including suspicion) Patients who were judged to be unsuitable for participating in this study by the doctor in charge. *Lung cancer nothing special
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| There are no evaluation items such as primary outcomes for this observational research, which constructs a database and AI. | — |
Secondary
| Measure | Time frame |
|---|---|
| Same as above. | — |
Countries
Japan
Contacts
Public ContactYayoi Natsume
National Institutes of Biomedical Innovation, Health and Nutrition Laboratory of Bioinformatics
Outcome results
None listed